ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

[News]

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

More... (http://www.news-medical.net/news/20100331/ViroPharma-initiates-Phase-2-clinical-study-to-evaluate-Cinryze.aspx)